Cargando…
Ischemic and Bleeding Risk After Percutaneous Coronary Intervention in Patients With Prior Ischemic and Hemorrhagic Stroke
BACKGROUND: Prior stroke is regarded as risk factor for bleeding after percutaneous coronary intervention (PCI). However, there is a paucity of data on detailed bleeding risk of patients with prior hemorrhagic and ischemic strokes after PCI. METHODS AND RESULTS: In a pooled cohort of 19 475 patients...
Autores principales: | Natsuaki, Masahiro, Morimoto, Takeshi, Watanabe, Hirotoshi, Nakagawa, Yoshihisa, Furukawa, Yutaka, Kadota, Kazushige, Akasaka, Takashi, Hanaoka, Keiichi Igarashi, Kozuma, Ken, Tanabe, Kengo, Morino, Yoshihiro, Muramatsu, Toshiya, Kimura, Takeshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6915281/ https://www.ncbi.nlm.nih.gov/pubmed/31701821 http://dx.doi.org/10.1161/JAHA.119.013356 |
Ejemplares similares
-
Prediction of Thrombotic and Bleeding Events After Percutaneous Coronary Intervention: CREDO‐Kyoto Thrombotic and Bleeding Risk Scores
por: Natsuaki, Masahiro, et al.
Publicado: (2018) -
Prognostic Impact of Baseline Hemoglobin Levels on Long‐Term Thrombotic and Bleeding Events After Percutaneous Coronary Interventions
por: Nagao, Kazuya, et al.
Publicado: (2019) -
Impact of Angiographic Residual Stenosis on Clinical Outcomes After New‐Generation Drug‐Eluting Stents Implantation: Insights From a Pooled Analysis of the RESET and NEXT Trials
por: Watanabe, Hiroki, et al.
Publicado: (2018) -
One-year clinical outcomes of patients with versus without acute coronary syndrome with 3-month duration of dual antiplatelet therapy after everolimus-eluting stent implantation
por: Natsuaki, Masahiro, et al.
Publicado: (2020) -
One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial
por: Natsuaki, Masahiro, et al.
Publicado: (2015)